Studies and clinical experiences suggest that maintaining weight loss achieved through GLP-1 receptor agonists like semaglutide requires ongoing lifestyle modifications and possibly continuation of the medication
Our findings demonstrated that the SFN-treated group exhibited significantly lower expression of K16, K17, and Ki67 compared to the IMQ group (Fig
2 Data from a cohort of patients with a high risk for cardiovascular events (the CORE-Thailand Registry) show that 83.8% of patients who had established atherosclerotic CVD (ASCVD) and multiple CV risk factors have either diabetes or impaired fasting glucose
Always disclose all medications to your provider so they can adjust your tirzepatide dose accordingly
grant nurse practitioners full practice authority meaning NPs can evaluate, diagnose, treat, prescribe medications, and operate their own independent clinical practice without any requirement for physician oversight or a collaborative agreement
Over three years, this translated to roughly 12 fewer serious events in total per 1,000 people using GLP-1 drugs including two fewer deaths